annual CFO:
-$181.39M-$30.28M(-20.04%)Summary
- As of today (September 10, 2025), XENE annual cash flow from operations is -$181.39 million, with the most recent change of -$30.28 million (-20.04%) on December 31, 2024.
- During the last 3 years, XENE annual CFO has fallen by -$111.89 million (-160.98%).
- XENE annual CFO is now -498.02% below its all-time high of $45.57 million, reached on December 31, 2012.
Performance
XENE Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$66.53M-$4.88M(-7.91%)Summary
- As of today (September 10, 2025), XENE quarterly cash flow from operations is -$66.53 million, with the most recent change of -$4.88 million (-7.91%) on June 1, 2025.
- Over the past year, XENE quarterly CFO has dropped by -$35.93 million (-117.39%).
- XENE quarterly CFO is now -434.41% below its all-time high of $19.90 million, reached on December 31, 2019.
Performance
XENE quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$230.56M-$35.93M(-18.46%)Summary
- As of today (September 10, 2025), XENE TTM cash flow from operations is -$230.56 million, with the most recent change of -$35.93 million (-18.46%) on June 1, 2025.
- Over the past year, XENE TTM CFO has dropped by -$77.62 million (-50.76%).
- XENE TTM CFO is now -7249.73% below its all-time high of $3.22 million, reached on September 30, 2014.
Performance
XENE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
XENE Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.0% | -117.4% | -50.8% |
| 3 y3 years | -161.0% | -297.8% | -229.5% |
| 5 y5 years | -3747.9% | -537.2% | -2011.5% |
XENE Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -161.0% | at low | -297.8% | at low | -229.5% | at low |
| 5 y | 5-year | -3747.9% | at low | -537.2% | at low | -2011.5% | at low |
| alltime | all time | -498.0% | at low | -434.4% | at low | -7249.7% | at low |
XENE Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$66.53M(+7.9%) | -$230.56M(+18.5%) |
| Mar 2025 | - | -$61.65M(+20.4%) | -$194.63M(+8.6%) |
| Dec 2024 | -$181.39M(+20.0%) | -$51.19M(-0.0%) | -$179.17M(+10.8%) |
| Sep 2024 | - | -$51.19M(+67.3%) | -$161.67M(+5.7%) |
| Jun 2024 | - | -$30.60M(-33.7%) | -$152.93M(-1.8%) |
| Mar 2024 | - | -$46.19M(+37.1%) | -$155.79M(+8.2%) |
| Dec 2023 | -$151.11M(+49.6%) | -$33.69M(-20.6%) | -$144.01M(+2.7%) |
| Sep 2023 | - | -$42.45M(+26.9%) | -$140.18M(+10.3%) |
| Jun 2023 | - | -$33.46M(-2.8%) | -$127.10M(+15.2%) |
| Mar 2023 | - | -$34.41M(+15.3%) | -$110.37M(+16.9%) |
| Dec 2022 | -$101.03M(+45.4%) | -$29.85M(+1.6%) | -$94.39M(+10.9%) |
| Sep 2022 | - | -$29.38M(+75.7%) | -$85.08M(+21.6%) |
| Jun 2022 | - | -$16.73M(-9.2%) | -$69.97M(+4.7%) |
| Mar 2022 | - | -$18.43M(-10.3%) | -$66.84M(-3.3%) |
| Dec 2021 | -$69.50M(+44.4%) | -$20.55M(+44.1%) | -$69.12M(+10.4%) |
| Sep 2021 | - | -$14.26M(+4.9%) | -$62.63M(+3.8%) |
| Jun 2021 | - | -$13.60M(-34.3%) | -$60.34M(+5.5%) |
| Mar 2021 | - | -$20.71M(+47.4%) | -$57.18M(+15.4%) |
| Dec 2020 | -$48.12M(+920.9%) | -$14.05M(+17.4%) | -$49.54M(+217.8%) |
| Sep 2020 | - | -$11.97M(+14.7%) | -$15.59M(+42.8%) |
| Jun 2020 | - | -$10.44M(-20.1%) | -$10.92M(+20.6%) |
| Mar 2020 | - | -$13.07M(-165.7%) | -$9.06M(+94.5%) |
| Dec 2019 | -$4.71M | $19.90M(-372.3%) | -$4.66M(-85.3%) |
| Sep 2019 | - | -$7.31M(-14.8%) | -$31.57M(-16.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$8.58M(-1.0%) | -$37.71M(+9.2%) |
| Mar 2019 | - | -$8.67M(+23.4%) | -$34.53M(+1.3%) |
| Dec 2018 | -$34.72M(+20.9%) | -$7.02M(-47.8%) | -$34.08M(+1.7%) |
| Sep 2018 | - | -$13.44M(+148.9%) | -$33.52M(+12.5%) |
| Jun 2018 | - | -$5.40M(-34.3%) | -$29.79M(-4.2%) |
| Mar 2018 | - | -$8.22M(+27.2%) | -$31.09M(+6.0%) |
| Dec 2017 | -$28.73M(+46.8%) | -$6.46M(-33.5%) | -$29.33M(+8.1%) |
| Sep 2017 | - | -$9.71M(+45.0%) | -$27.14M(+24.1%) |
| Jun 2017 | - | -$6.70M(+3.7%) | -$21.88M(+4.5%) |
| Mar 2017 | - | -$6.46M(+51.1%) | -$20.94M(+7.8%) |
| Dec 2016 | -$19.57M(+8.1%) | -$4.28M(-3.8%) | -$19.43M(-3.9%) |
| Sep 2016 | - | -$4.45M(-22.9%) | -$20.22M(+0.9%) |
| Jun 2016 | - | -$5.76M(+16.6%) | -$20.05M(+19.7%) |
| Mar 2016 | - | -$4.94M(-2.4%) | -$16.74M(-3.5%) |
| Dec 2015 | -$18.10M(-6905.6%) | -$5.07M(+18.7%) | -$17.34M(+13.8%) |
| Sep 2015 | - | -$4.27M(+73.5%) | -$15.24M(+225.6%) |
| Jun 2015 | - | -$2.46M(-55.6%) | -$4.68M(+5.3%) |
| Mar 2015 | - | -$5.55M(+87.0%) | -$4.45M(-1819.4%) |
| Dec 2014 | $266.00K(-108.0%) | -$2.97M(-147.1%) | $258.60K(-92.0%) |
| Sep 2014 | - | $6.29M(-382.8%) | $3.22M(-205.1%) |
| Jun 2014 | - | -$2.23M(+164.3%) | -$3.07M(+264.3%) |
| Mar 2014 | - | -$842.00K | -$842.00K |
| Dec 2013 | -$3.32M(-107.3%) | - | - |
| Dec 2012 | $45.57M(-432.9%) | - | - |
| Dec 2011 | -$13.69M | - | - |
FAQ
- What is Xenon Pharmaceuticals Inc. annual cash flow from operations?
- What is the all time high annual CFO for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. annual CFO year-on-year change?
- What is Xenon Pharmaceuticals Inc. quarterly cash flow from operations?
- What is the all time high quarterly CFO for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. quarterly CFO year-on-year change?
- What is Xenon Pharmaceuticals Inc. TTM cash flow from operations?
- What is the all time high TTM CFO for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. TTM CFO year-on-year change?
What is Xenon Pharmaceuticals Inc. annual cash flow from operations?
The current annual CFO of XENE is -$181.39M
What is the all time high annual CFO for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high annual cash flow from operations is $45.57M
What is Xenon Pharmaceuticals Inc. annual CFO year-on-year change?
Over the past year, XENE annual cash flow from operations has changed by -$30.28M (-20.04%)
What is Xenon Pharmaceuticals Inc. quarterly cash flow from operations?
The current quarterly CFO of XENE is -$66.53M
What is the all time high quarterly CFO for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high quarterly cash flow from operations is $19.90M
What is Xenon Pharmaceuticals Inc. quarterly CFO year-on-year change?
Over the past year, XENE quarterly cash flow from operations has changed by -$35.93M (-117.39%)
What is Xenon Pharmaceuticals Inc. TTM cash flow from operations?
The current TTM CFO of XENE is -$230.56M
What is the all time high TTM CFO for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high TTM cash flow from operations is $3.22M
What is Xenon Pharmaceuticals Inc. TTM CFO year-on-year change?
Over the past year, XENE TTM cash flow from operations has changed by -$77.62M (-50.76%)